A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types
A study evaluating the drug levels of ipilimumab alone and in combination with nivolumab applied under the skin in various tumor types
Tumor
DRUG: ipilimumab|DRUG: nivolumab|DRUG: ENHANZE (rHuPH20)|DRUG: nivolumab
Part 1 Arm A: Average concentration of ipilimumab (Cavg21d), Day 21|Part 1 Arm A: Area under the concentration in ipilimumab AUC(0-21d), Day 21|Part 1 Arm A: Maximum observed serum concentration of ipilimumab (Cmax), Up to 21 days|Part 1 Arm A: Observed concentration of ipilimumab at 21 days post dose (C21d), Day 21|Part 1 Arm A: Time of maximum observed concentration in ipilimumab (Tmax), Up to 21 days|Part 2 Arm A: Average concentration in ipilimumab (Cavg42d), Day 42|Part 2 Arm A: Area under the concentration in ipilimumab AUC(0-42d), Day 42|Part 2 Arm A: Maximum observed serum Concentration of Ipilimumab (Cmax), Up to 42 days|Part 2 Arm A: Observed concentration in ipilimumab (C42d), Day 42|Part 2 Arm A: Time of maximum observed concentration in ipilimumab (Tmax), Up to 42 days|Part 2 Arm B: Average concentration of Ipilimumab at 21 days post dose (Cavg21d), Day 21|Part 2 Arm B: Area Under the Concentration in Ipilimumab AUC(0-21d), Day 21|Part 2 Arm B: Maximum observed serum Concentration in Ipilimumab (Cmax), Up to 21 days|Part 2 Arm B: Observed concentration of ipilimumab at 21 days post dose (C21d), Day 21|Part 2 Arm B: Time of maximum observed concentration in Ipilimumab (Tmax), Up to 21 days
Part 1 Arm B: Average concentration of ipilimumab without rHuPH20 (Cavg21d), Day 21|Part 1 Arm B: Area under the concentration in ipilimumab without rHuPH20 AUC(0-21d), Day 21|Part 1 Arm B: Maximum observed serum concentration of ipilimumab without rHuPH20 (Cmax), Up to 21 days|Part 1 Arm B: Observed concentration of ipilimumab without rHuPH20 at 21 days post dose (C21d), Day 21|Part 1 Arm B: Time of maximum observed concentration in ipilimumab without rHuPH20 (Tmax), Up to 21 days|Incidence of adverse events (AE's), Up to 2.5 years|Incidence of serious adverse events (SAEs), Up to 5 years|Incidence of AE's leading to discontinuation, Up to 2.5 years|Incidence of death, Up to 2.5 years|Incidence of laboratory abnormalities, Up to 2.5 years|Instance of Anaphylactic occurring within 2 days of study drug administration, Up to 2.5 years|Instance of hypersensitivity occurring within 2 days of study drug administration, Up to 2.5 years|Incidence of hypersensitivity occurring within 2 days of study drug administration, Up to 2.5 years|Incidence of infusion reactions occurring within 2 days of study drug administration, Up to 2.5 years|Incidence of injection occurring within 2 days of study drug administration, Up to 2.5 years|Percentage of participants who develop anti-ipilimumab antibodies, Up to 2.5 years|Percentage of participants who develop anti-nivolumab antibodies, Up to 2.5 years|Percentage of participants who have developed neutralizing antibodies, Up to 2.5 years
A study evaluating the drug levels of ipilimumab alone and in combination with nivolumab applied under the skin in various tumor types